主 讲 人 ：徐峻
时 间 ：2025-10-16 14:00
地 点 ：智能信息技术研究中心
承办 部门 ：智能信息技术研究中心
热烈欢迎广大师生参加
主讲人简介：徐峻教授现任中国科学院医学技术研究所生物医药大数据研究中心主任、中山大学教授、中科院深圳先进研究院特聘研究员、香港中文大学(深圳)铁代谢实验室主任、英国皇家化学会会士。 1989年毕业于中国科学技术大学。硕士和博士论文的题目分别是化学专家系统的建立和计算机辅助有机合成路线设计。他的AI研究历程可以追溯到上世纪80年代。主攻人工智能和图论算法在药物设计中的应用，是子图匹配、多维蛋白质NMR结构解析、分子图簇分析、关系式化学结构数据库搜索引擎、机器学习辅助药物设计等算法的作者。徐峻1990-1993年分别在澳洲国立大学、加拿大麦基尔大学做博士后研究。历任美国TRIPOS分子设计公司资深科学家，BIO-RAD研发部总监，德国Boehringer Ingelheim制药公司药物设计主管科学家，美国BioFocus-DPI制药公司药物设计总监和Fellow。徐教授长期在第一线从事方法学算法研究和药物发现实验研究。在方法学研究基础上，发现了多种抗代谢疾病药物、抗癌、抗γ型人类疱疹病毒、抗甲流、抗EBV等病原微生物的新先导化合物和新靶标。徐峻2009年归国创建中山大学药物分子设计研究中心，涵盖药物设计、结构生物学、天然药物化学、药物筛选与机理研究。徐峻是国家“新药创制重大科技专项”、广东省生物大数据重大专项、广州市药物创新重大科技专项的主持人。徐峻以第一或通讯作者在国际主流杂志发表研究论文140多篇，30多项授权药学发明专利实现转化，抗复发性肿瘤首创药物即将完成IND研究。《药物发现方法学——研究范式的演化》(科学出版社，2024年，ISBN: 978-7-03-076100-2)是徐教授的代表作，介绍了AI辅助药物发现的底层逻辑及技术演化。Professor Jun Xu is currently the Director of the Biomedical Data Center at the Institute of Medical Technology, Prof. of Sun Yat-Sen University, Chinese Academy of Sciences, a Distinguished Research Fellow at the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Director of the Ferroptosis Laboratory at the Chinese University of Hong Kong (Shenzhen), and a Fellow of the Royal Society of Chemistry (FRSC). He graduated from the University of Science and Technology of China in 1989. His master's and doctoral dissertations were on the establishment of chemical expert systems and computer-assisted organic synthesis design, respectively. His AI research experience dates back to the 1980s. He specializes in the application of artificial intelligence and graph theory algorithms in drug design. He is the author of algorithms for subgraph matching, multidimensional protein NMR structure analyses, molecular graph cluster analysis, relational chemical structure database search engines, and machine learning-assisted drug design. From 1990 to 1993, Jun Xu conducted postdoctoral research at the Australian National University and McGill University in Canada, respectively. He has served as a Senior Scientist at TRIPOS in the United States, Director of R&D at BIO-RAD, Principal Scientist for Drug Design at Boehringer Ingelheim Pharmaceuticals, and Director and Fellow of Drug Design at BioFocus-DPI Pharmaceuticals in the United States. Professor Xu has long been engaged in frontline research in methodological algorithms and experimental drug discovery. Based on methodological research, new lead compounds and targets have been discove
